Regenerative Patch Technologies

Jane Lebkowski, Ph.D., President
Menlo Park, CA
Regenerative Patch Technologies (RPT) was founded to advance the development of bio-engineered implants for the treatment of vision loss. RPT’s lead product is called CPCB-RPE1 and is a composite implant consisting of human retinal pigmented epithelial (RPE) cells polarized on an ultrathin, biocompatible, parylene membrane. The properties of the parylene membrane are designed to mimic those of the native Bruch’s membrane. This implant serves as a tissue replacement for the diseased RPE cell layer and Bruch’s membrane found in patients with the advanced form of dry age-related macular degeneration. The company has now completed enrollment and one year follow-up subjects in a Phase I/IIa clinical trial and is progressing a Phase IIb clinical trial in patients with geographic atrophy.

By using this website you agree to accept our Privacy Policy and Terms & Conditions